BCR and B-cell chronic lymphocytic leukemia: The advent of the BCR inhibitors and venetoclax has fundamentally changed the paradigm of CLL management and brought unprecedented benefits to patients, particularly those with historically poor outcomes with CIT (for example, those with del(17p) orTP53 abnormalities).